Heart transplantation using allografts from older donors: multicenter study results by Roig, Eulàlia et al.
The Journal of Heart and Lung Transplantation. 2015; 34(6): 790-796 
Heart transplantation using allografts from older donors: 
multicenter study results 
Eulàlia Roig, MD, PhD
a
, Luís Almenar, MD, PhD
b
, Marisa Crespo-Leiro, MD, 
PhD
c
, Javier Segovia, MD, PhD
d
, Sònia Mirabet, MD
a
, Juan Delgado, MD, PhD
e
, 
Felix Pérez-Villa, MD, PhD
f
, Jose Luís Lambert, MD, PhD
g
, M. Teresa Blasco, 
MD
h
, Javier Muñiz, MD, PhD
i
, the rest of the participants of the Spanish Heart 
Transplantation Registry 
a Servicio de Cardiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain 
b Servicio de Cardiologia, Hospital Universitario y Politecnico La Fe, Valencia, Spain 
c Servicio de Cardiologia, Hospital Universitario A Coruña, A Coruña, Spain 
d Servicio de Cardiologia, Clinica Puerta de Hierro, Majadahonda, Madrid, Spain 
e Servicio de Cardiologia, Hospital 12 de Octubre, Madrid, Spain 
f Servicio de Cardiologia, Institut Clínic del Torax, Barcelona, Spain 
g Servicio de Cardiologia, Hospital Central de Asturias, Spain 
h Servicio de Cardiologia, Hospital Miguel Servet, Zaragoza, Spain 
i Instituto de Ciencias de la Salud, Universidad de A Coruña, A Coruña, Spain 
Abstract. 
BACKGROUND. The lengthy waiting time for heart transplantation is associated with high mortality. To 
increase the number of donors, new strategies have emerged, including the use of hearts from donors ≥50 
years old. However, this practice remains controversial. The aim of this study was to evaluate outcomes of 
patients receiving heart transplants from older donors. 
METHODS. We retrospectively analyzed 2,102 consecutive heart transplants in 8 Spanish hospitals from 
1998 to 2010. Acute and overall mortality were compared in patients with grafts from donors ≥50 years old 
versus grafts from younger donors. 
RESULTS. There were 1,758 (84%) transplanted grafts from donors < 50 years old (Group I) and 344 (16%) 
from donors ≥50 years old (Group II). Group I had more male donors than Group II (71% vs 57%, p = 
0.0001). The incidence of cardiovascular risk factors was higher in older donors. There were no differences in 
acute mortality or acute rejection episodes between the 2 groups. Global mortality was higher in Group II 
(rate ratio, 1.40; 95% confidence interval, 1.18–1.67; p = 0.001) than in Group I. After adjusting for donor 
cause of death, donor smoking history, recipient age, induction therapy, and cyclosporine therapy, the 
differences lost significance. Group II had a higher incidence of coronary allograft vasculopathy at 5 years 
(rate ratio, 1.67; 95% confidence interval, 1.22–2.27; p = 0.001). 
CONCLUSIONS. There were no differences in acute and overall mortality after adjusting for confounding 
factors. However, there was a midterm increased risk of coronary allograft vasculopathy with the use of older 
donors. Careful selection of recipients and close monitoring of coronary allograft vasculopathy are warranted 
in these patients. 
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Heart transplantation (HTx) improves survival in selected patients with end-stage congestive 
heart failure.
1 
In Spain, as in many countries, the availability of cardiac grafts has decreased, while 
the number of patients with heart failure listed for HTx remains stable or has increased.
2 
Despite 
the increased use of a left ventricular assist device (LVAD) as a bridge to HTx to wait for a 
younger donor, this approach has some risks that can affect outcome after transplantation. For 
example, receptor sensitization and higher risk of bleeding or device infection
3 
may affect survival 
after HTx. Also, the LVAD increases HTx cost, and some countries indicate its use only in highly 
selected patients. New strategies have been developed to increase the number of available grafts, 
including the acceptance of older donors. Although the upper donor age limit is 60 to 65 years, 
using donors > 50 years old raises concerns about outcomes, such as whether patients with grafts 
from older donors have greater susceptibility to early coronary allograft vasculopathy (CAV) and 
higher mortality.
4,5 
The aim of this multicenter study was to investigate outcomes of patients 
receiving grafts from donors ≥ 50 years old. 
Methods 
From January 1998 to December 2010, HTx programs at 8 centers in Spain performed 2,102 
consecutive HTx surgeries. Only patients > 16 years old were included in the study, and patients 
were divided into 2 groups according to donor age. Group I had received grafts from donors < 50 
years old, and Group II had received grafts from donors ≥ 50 years old. Patients with an additional 
organ transplantation or heart re-transplantation were excluded from the study. 
 
Donor information and recipients’ clinical HTx data, coronary allograft vasculopathy 
incidence, and survival data are routinely recorded in the Spanish Register for Heart 
Transplantation. Pre-transplant clinical variables analyzed for recipients were age, sex, and the 
etiology of heart failure. Donor-related variables were age, cause of death, and history of 
dyslipidemia, hypertension, diabetes mellitus, and smoking. Donor diabetes mellitus type 1 or type 
2 insulin-dependent was a criterion for non-acceptance. Post-HTx data analysis included ischemic 
time, acute rejection episodes, CAV, and overall mortality. Coronary angiography was performed 
to evaluate the presence of coronary disease related to the donor graft at 1 month and 1, 5, and 10 
years after transplantation and when clinically indicated. Endomyocardial biopsies, 
echocardiography, and patient follow-up were done as needed at each center and according to its 
own protocol. Acute rejection was diagnosed when the pathologist graded it as AR ≥ 2R following 
the International Society for Heart and Lung Transplantation (ISHLT) classification. The diagnosis 
of CAV followed the ISHLT classification: not significant (CAV0), mild (CAV1), moderate 
(CAV2), and severe (CAV3)
6
; the presence of CAV1 through CAV3 was considered a CAV 
diagnosis. All centers used triple immunosuppressive therapy comprising steroids, cyclosporine or 
tacrolimus, mycophenolate mofetil or mycophenolic acid, or azathioprine or rapamycin or 
everolimus. Cytomegalovirus prophylaxis was given when there was a (donor
+
/receptor

) 
mismatch or evidence of positive CMV on polymerase chain reaction. All patients provided signed 
informed consent for inclusion in the HTx register and related data analysis. 
Statistical analysis 
Donor and recipient variables were compared between Groups I and II (donor < 50 years old 
and donor ≥ 50 years old, respectively). Differences between groups were analyzed by the Pearson 
chi-square test for qualitative variables or Mann-Whitney U non-parametric test for continuous 
variables. Acute mortality included all deaths during the admission for the HTx procedure or, 
among patients discharged alive after the HTx procedure, all deaths during the first month after 
HTx. Acute mortality was computed as a proportion with its 95% confidence interval (CI), and 
logistic regression was used to compute crude and adjusted odds ratios between groups. Global 
mortality rate and CAV incidence per 1,000 patient-years with 95% CI were calculated for each 
donor age group. Relative risks between groups were computed by means of a Poisson regression 
model with Group I always the reference group. Potential confounders both for the logistic 
regression (for acute mortality) and for the Poisson models (for global mortality) were selected 
among variables associated with mortality and the inclusion of which individually changed > 3% 
the estimate (either the rate ratio [RR] or the odds ratio [OR]) from the unadjusted one. 
 
A competing risks analysis was used to adjust CAV RRs.
7 
Differences in survival between the 
2 groups were examined using a Kaplan-Meier actuarial analysis and compared with a log-rank 
test. A p-value < 0.05 was considered significant. Data were analyzed using Stata version 12.0 
(StataCorp LP, College Station, TX). 
Results 
Overall, 1,758 (83%) recipients received grafts from donors < 50 years old (Group I), and 344 
(16%) recipients received grafts from donors ≥ 50 years old (Group II); only 18 (5%) donors were 
≥ 60 years old. The number of transplants by year and donor age is shown in Table 1; the use of 
older donors has increased in recent years. There was no difference between age groups in the 
need for urgent HTx (27.9% in Group I vs 25.7% in Group II). Similarly, although there was a 
trend toward longer ischemic time with the use of older donors, ischemic time did not differ 
between groups (188 + 64 minutes vs 194 + 65 minutes, p = 0.09). Clinical characteristics of 
donors are summarized in Table 2. Group II had a higher percentage of female donors (28.6% vs 
42.4%, p = 0.0001). Cerebral trauma as a cause of death was higher in Group I (45.7% vs 16.2%, 
p = 0.0001), but cerebrovascular accidents were more prevalent in Group II (30.1% vs 49.9%, p = 
0.0001). Three coronary risk factors — hypertension, dyslipidemia, and smoking history — were 
more prevalent in Group II, but there was no difference between donor groups in diabetes mellitus 
incidence. Clinical characteristics of recipient groups according to donor age are shown in Table 3. 
Group II recipients were older (52 + 11 years old vs 55 + 10 years old, p = 0.0001) and had higher 
incidence of hypertension (29% vs 37%, p = 0.004) and diabetes mellitus (13.9% vs 19.5%, p = 
0.007). Induction therapy with OKT3 was more prevalent in Group I, and induction therapy with 
basiliximab was more prevalent in Group II. Use of tacrolimus and mycophenolate mofetil as 
immunosuppressive therapy was more prevalent in Group II. Mean follow-up duration was 5.7 + 
3.8 years for Group I and 5.7 + 3.7 years for Group II. 
Table 1. Number of Heart Transplantations by Donor Age per Year 
 Donor < 50 years old  Donor ≥ 50 years old 
Year of HTx n %  n % 
      
1998 179 89.5  21 10.5 
1999 181 89.2  22 10.8 
2000 181 88.3  24 11.7 
2001 164 83.2  33 16.8 
2002 141 84.9  25 15.1 
2003 132 86.8  20 13.2 
2004 125 84.5  23 15.5 
2005 140 85.9  23 14.1 
2006 116 82.9  24 17.1 
2007 102 80.3  25 19.7 
2008 117 79.1  31 20.9 
2009 97 77.6  28 22.4 
2010 83 64.8  45 35.2 
      
 
HTx, heart transplantation. 
  
Table 2. Donor Clinical Characteristics by Donor Age Group 
 Donor < 50 years old  Donor ≥ 50 years old  
 n = 1,758  n = 344 p-valuea 
     
Males 71.5  57.6 < 0.001 
Cause of death     
Cerebral trauma 45.7  16.2 < 0.001 
CVA 30.3  49.9  
Other 25.5  34.8  
CMV serology (+) 71.6  81.9 < 0.001 
Hypertension 5.6  19.7 < 0.001 
Dyslipidemia 3.1  9.5 < 0.001 
Diabetes mellitus ID 0.7  0.6 0.808 
Smoking history     
Smoker (within 1 year) 22.6  33.1  
Ex-smoker (1–10 years) 17.7  18.8 < 0.001 
Non-smoker 59.6  47.9  
Dopamine (μg/Kg/min)     
No 49.1  59.6 0.002 
0–5 20.0  16.3  
> 5 30.9  24.1  
Dobutamine (μg/Kg/min)     
No 91.9  95.3 0.041 
0–5 2.2  2.0  
> 5 6.0  2.6  
Noradrenaline (μg/Kg/min)     
No 55.0  50.3 0.261 
0–0.05 7.6  10.2  
0.06–0.10 8.0  10.5  
0.11–0.20 9.9  11  
0.21–0.5 12.3  10.8  
> 0.5 7.2  7.3  
     
 
All results expressed as percentages. CMV, cytomegalovirus; CVA, cerebrovascular accident; ID, insulin-dependent. 
a Pearson chi-square test. 
There were no differences between Groups I and II in the number of acute rejection episodes (≥ 
2R), rejection with hemodynamic compromise, or any treated rejection episode during follow-up 
(42.6% vs 40.1%, p = 0.39). Despite a ack of significant differences between the 2 groups in CAV 
incidence at 1 year, the incidence was significantly higher in Group II at 5-year follow-up (28.4% 
vs 53.0%; RR, 1.87; 95% CI, 1.37–2.55; p = 0.0001) and after 10 years (31.6% vs 49%; RR, 1.55; 
95% CI, 1.19–2.02; p = 0.001), and the differences persisted after adjusting for competitive risks 
(Table 4). 
 
Overall mortality was significantly higher in Group II than in Group I. Multivariate analysis 
showed an increased risk of death with the use of older donors (RR, 1.40; 95% CI, 1.18–1.67; p < 
0.001). However, the significance was lost after adjusting for donor cause of death, donor smoking 
history, recipient age, and induction and cyclosporine therapy. Survival at 30 days was 88% (95% 
CI, 86.9–89.6). There were no differences between the 2 groups in crude acute mortality and after 
adjusting for donor cause of death, ischemic time, induction therapy, cyclosporine, tacrolimus, and 
mycophenolate mofetil therapies (Table 5). Survival curves showed no differences in acute 
mortality between Group I and Group II but increased overall crude mortality in Group II (Figure 
1). When comparing the effect of donor age on survival among recipients of different age, there 
was a tendency for a better survival among recipients who received a heart from a donor < 50 
years old, but this difference was statistically significant only in the group of recipients > 60 years 
old, and the effect disappeared after adjustment for confounding factors. 
  
Table 3. Recipient Clinical Characteristics by Donor Age Group 
 Donor < 50 years old  Donor ≥ 50 years old  
Variable n = 1,758  n = 344 p-valuea 
     
Sex     
Male 80.7  79.1 0.481 
Female 19.3  20.9  
Age group     
16–60 years 74.1  64.0 0.000 
> 60 years 25.9  36.0  
Antecedents of hypertension     
No 71.1  63.3 0.004 
Yes 29.4  36.6  
Hypercholesterolemia     
No 63.6  66.2 0.366 
Yes 36.3  33.7  
Diabetes mellitus ID     
No 86.1  80.5 0.007 
Yes 13.9  19.7  
Smoking history     
Smoker (within 1 year) 25.7  21.8 0.209 
Ex-smoker (1–10 years) 32.0  32.5  
Non-smoker 42.2  45.6  
CMV serology     
Positive 82.4  86.0 0.159 
Negative 17.4  14.0  
HTx code     
Urgent 27.9  25.7 0.416 
Elective 72.1  74.4  
Induction therapy     
None 5.6  6.4 < 0.001 
ALG-ATG 8.2  9.6  
OKT3 35.0  23.3  
Daclizumab 13.1  10.2  
Basiliximab 32.4  41.9  
Other 5.7  8.7  
Immunosuppressive treatment     
Cyclosporine 67.4  58.4 0.001 
Tacrolimus 23.8  30.2 0.011 
Azathioprine 26.3  17.4 0.000 
MMF 66.8  74.1 0.008 
EC-MPS 0.7  0.6 0.750 
Rapamycin 2.3  0.6 0.040 
Everolimus 1.9  2.6 0.370 
Steroids 95.5  94.8 0.550 
     
Variable Mean (SD)  Mean (SD) p-valuea 
     
Recipient age 52 ± 11  55 ± 10 0.000 
Ischemic time (minutes) 188 ± 64  194 ± 65 0.095 
     
 
All results expressed as percentages. ALG-ATG, anti-thymoglobulin; CMV, cytomegalovirus; EC-MPS, mycophenolic 
acid; HTx, heart transplantation; ID, insulin-dependent; MMF, mycophenolate mofetil; OKT-3, muromonab-CD3; SMF, 
mycophenolic acid. 
a Pearson chi-square test 
  
Table 4. Coronary Allograft Vasculopathy Incidence per 1,000 Patients/Year Comparing Recipients Transplanted with 
Donors < 50 Years Old or ≥ 50 Years Old 
 Patient-years CAV Rate 95% CI  
      
1-year CAV incidence      
Donor < 50 years old 1,438.6 49 34.1 25.7 45.1 
Donor ≥ 50 years old 262.0 13 49.6 28.8 85.5 
5-year CAV incidence      
Donor < 50 years old 5,991.0 170 28.4 24.4 33.0 
Donor ≥ 50 years old 980.4 52 53.0 40.4 69.6 
10-year CAV incidence      
Donor < 50 years old 9,091.8 287 31.6 28.1 35.4 
Donor ≥ 50 years old 1,368.7 67 49.0 38.5 62.2 
      
 RR 95% CI  p-value  
      
Unadjusted for competitive risks      
1 year 1.46 0.79 2.68 0.228  
5 years 1.87 1.37 2.55 0.000  
10 years 1.55 1.19 2.02 0.001  
Adjusted for competitive risks      
1 year 1.39 0.75 2.56 0.296  
5 years 1.67 1.22 2.27 0.001  
10 years 1.35 1.03 1.76 0.028  
      
 
CAV, coronary allograft vasculopathy; CI, confidence interval; RR, rate ratio. 
Table 5. Acute Mortality (%) and Global Mortality per 1,000 Patients/Year and Comparison of Recipients Transplanted 
with Donors < 50 Years Old or ≥ 50 Years Old 
      
Global mortality Patient-years Deaths Rate 95% CI  
Donor < 50 years old 11,311.1 709 62.7 58.2 67.5 
Donor ≥ 50 years old 1,741.7 153 87.9 75.0 102.9 
Acute mortalitya Patients Deaths % 95% CI  
Donor < 50 years old 1.758 267 15.2 13.5 17.0 
Donor ≥ 50 years old 344 65 18.9 14.9 23.4 
Global mortality RR 95% CI  p-value RC (%) 
Unadjusted 1.40 1.18 1.67 < 0.001  
Adjustedb 1.19 0.96 1.47 0.111 15.27 
Acute mortality OR 95% CI  p-value RC (%) 
Unadjusted 1.30 0.96 1.76 0.085  
Adjustedc 1.17 0.81 1.70 0.407 10.08 
      
 
CI, confidence interval; OR, odds ratio; RC, relative change; RR, rate ratio. 
a Includes all deaths during the admission for the heart transplantation procedure or, among patients discharged alive after 
the procedure, all deaths during the first month after heart transplantation. 
b Adjusted by donor cause of death, donor smoking history, age, induction therapy, cyclosporine, and mycophenolate 
mofetil. 
c Adjusted by age, ischemic time, cyclosporine, tacrolimus, and mycophenolate mofetil. 
 
  
 
 
 
Figure 1. Differences in survival between the 2 groups using a 
Kaplan-Meier actuarial analysis and compared with a log-rank test. 
Overall crude mortality was higher with the use of older donors (p < 
0.001) 
Discussion 
The present study is one of the largest to analyze the survival after HTx of patients with grafts 
from older donors, having prospectively recruited patients from 8 centers in Spain that send their 
data to the Spanish Register for Heart Transplantation. Our analysis indicates that donors ≥ 50 
years old can be safely used for HTx: After adjusting for potential confounding factors, there were 
no differences in acute or overall mortality. 
 
Despite the gradually increasing use of older donors, there is still controversy concerning the 
prognosis of recipients who receive older grafts.
8–12
 Previous reports on the outcome of grafts from 
older donors are based on single-center studies with a small number of patients.
8,9
 Although some 
earlier studies reported increased in-hospital mortality after accepting older donors,
13–15
 we as well 
as others
9,16
 found no differences related to donor age in acute mortality in patients undergoing 
HTx. Advances in acute care after HTx can explain the differences between studies performed > 
10 years ago and more recent findings. In our study, the percentage of urgency codes and length of 
ischemic times were similar between the 2 groups, and we observed no differences in the severity 
of heart failure before HTx. 
 
Overall mortality was significantly higher in Group II. However, the differences disappear 
after adjustment for donor cause of death, donor smoking history, recipient age, induction therapy, 
and cyclosporine therapy. Recipient characteristics rather than donor age can influence graft 
survival. Although a donor’ s coronary risk factors may influence HTx outcome, this has been 
minimally addressed in previous studies of survival after HTx.
16,17 
In our study, although the 
overall incidence of risk factors was low, older donors had a higher rate of hypertension, 
dyslipidemia, and smoking, but there were no differences in diabetes mellitus rate between donor 
age groups. Careful donor selection is key, and diabetes mellitus, if severe, is generally an 
exclusion factor for donor acceptance. In our study, the acceptance rate of a donor with diabetes 
mellitus was < 1%. Hypertension has been associated with diastolic dysfunction, which is not well 
measured at the time of HTx but can result in increased stiffness of the heart and hypertrophy. 
However, these factors are not associated with worse outcomes.
18 
In disagreement with a previous 
study,
19
 we did not find a significant interaction between prolonged ischemic time and the use of 
old donors. In the study by Russo et al, 19 patients with an ischemic time > 5.5 hours had worse 
survival. Because the mean ischemic time of our patients undergoing HTx was shorter, we cannot 
rule out that with prolonged ischemic times the use of old donors can be associated with worse 
prognosis. Several scores
20,21 
have been proposed to evaluate donor risk and predict prognosis, 
suggesting that a model based on several factors would improve donor acceptance.
22
  
In this study, the group of older recipients (> 60 years old) received a higher proportion of 
hearts from old donors rather than younger donors (< 60 years), and older recipient age has been 
consistently associated with worse survival in analyses of the United Network for Organ Sharing 
Registry.
23,24 
Although induction therapy differed between the 2 study groups, this did not affect 
acute mortality (OKT3 was more frequently used with younger donor grafts, whereas the more 
recent use of older grafts coincided with increased use of basiliximab therapy). However, the 
influence of induction therapy on long-term prognosis is less clear.
25 
Because of changes in 
immunosuppressive therapy in recent years, tacrolimus was more frequently given to recipients 
transplanted with older donor grafts. Used in combination with tacrolimus, mycophenolate mofetil 
and prednisone could contribute to improve survival in heart transplant recipients with older 
donors; this has been reported as the best immunosuppressive combination in terms of its 
association with less acute rejection and better survival.
26 
After adjusting for confounding factors 
such as donor cause of death and smoking history and recipient age and immunosuppressive 
regimen, mortality was not increased with the use of older donors. However, the higher incidence 
of co-morbidities in older recipients could influence survival after HTx, especially the higher 
incidence of diabetes mellitus in Group II recipients. Diabetes mellitus has been associated with 
worse long-term outcome after HTx in previous studies.
17
 
 
In agreement with previous data, we found no differences between the 2 groups in acute 
rejection or any treated rejection episodes.
10 
In this study, the rejection rate was high compared 
with other more recent reports; differences in immunosuppressive protocols over time may explain 
the differences.
27 
The use of older donors was associated with an increased risk of CAV at 5-year 
and 10-year follow-up. Although several studies
8,10 
have observed no differences in CAV 
incidence between younger and older donors, a more recent United Network for Organ Sharing 
report identified older donor age as an independent risk factor for development of CAV regardless 
of the recipient’s age.4 
 
Because patients with end-stage heart failure have very high mortality while awaiting heart 
transplantation, implanting a LVAD to wait for what is considered a good donor is an alternative 
to the use of older donors.
3,28 
However, LVAD use also has limitations, such as high demand on 
resources and higher rate of infection, hemorrhage, or thrombosis with embolic events.
3,29,30 
Although the rate of complications is being reduced with the implantation of newer devices, the 
risk of sensitization has not decreased and is associated with increases in immunosuppressive 
regimens and in risk of rejection after transplantation.
31 
Long-term implantation of LVADs is 
infrequently used in Spain, but short-term LVAD implantation is widely used when there is 
hemodynamic instability and urgent HTx is needed.
2 
Spain’s comparatively short wait-list time (< 
6 months in 2012 for non-emergency HTx
32
)may explain the low LVAD implantation rate. 
Nonetheless, long-term LVAD programs are now becoming more common because patients with 
pulmonary hypertension or a large body surface area may wait longer for HTx. The progressive 
lack of younger donors has led to a more frequent use of grafts from older donors.
2 
The literature 
lacks studies that compare survival and cost/benefit achieved with both strategies. 
 
A limitation of this study is that it was a retrospective study. However, the study population is 
considered representative because all heart transplants performed in Spain are prospectively 
entered in the Spanish Register for Heart Transplantation. 
 
In conclusion, in this study, the use of selected grafts from donors ≥ 50 years old was safe. 
There were no differences in acute or long-term survival after adjusting for confounding factors 
such as recipient age or immunosuppressive regimen. However, there was a mid-term increased 
risk of coronary graft vasculopathy with the use of older donors. Careful selection of recipients 
and close monitoring of CAV are warranted in these patients. 
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